寡转移性宫颈癌根治性放疗后的结局与复发模式
该单中心研究纳入2002至2015年接受寡转移灶根治性放疗的38例宫颈癌患者,中位随访35.2个月,中位总生存50.7个月,2年和3年总生存率分别为74%和65%,中位无进展生存21.7个月,21例(55%)出现进展,仅1例野内失败,≥3级毒性发生率<3%。
要点
- 寡转移灶根治性放疗后中位总生存50.7个月,2年和3年总生存率分别为74%和65%。
- 中位无进展生存21.7个月,1年和2年无进展生存率分别为63%和48%。
- 38例中21例(55%)进展,仅1例野内失败,≥3级毒性发生率<3%。
核心结论
- 对经仔细选择的宫颈癌寡转移患者,根治性放疗可实现良好的局部控制、有利的结局甚至长期生存,且放疗相关毒性极小。
研究设计与样本
- 单中心研究,纳入2002至2015年接受寡转移灶根治性放疗的38例宫颈癌患者。
- 患者表现为同步(n=9)或异时(n=15)寡转移至锁骨上淋巴结,或纵隔(n=10)或肺(n=7)复发。
- 3例同时治疗锁骨上和纵隔部位,6例在治疗主动脉旁或盆腔复发的同时治疗寡转移灶。
- 多数接受化疗:诱导(n=5)、同步(n=24)或辅助(n=5)。
- 采用Kaplan-Meier法评估结局,Cox比例风险模型检验关联。
主要发现
- 中位随访35.2个月(范围3.1-94.7)。
- 自放疗结束起中位总生存50.7个月,2年和3年总生存率分别为74%和65%。
- 中位无进展生存21.7个月,1年和2年无进展生存率分别为63%和48%。
- 38例中21例(55%)进展,中位进展时间24.8个月;仅1例野内失败,区域复发10例、远处复发12例,2例同时出现区域和远处复发。
- 锁骨上病灶治疗后最常见复发部位为纵隔(n=7);寡转移灶治疗的≥3级毒性发生率<3%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Survival rates for women with metastatic cervical cancer are low, with limited management options. Definitive radiation therapy (RT) for oligometastatic disease has led to prolonged survival in other malignancies, but this approach has yet to be systematically studied for cervical cancer. METHODS AND MATERIALS: We evaluated 38 patients who received definitive RT to oligometastatic sites of cervical cancer at a single institution from 2002 to 2015. Patients presented with synchronous (n=9) or metachronous (n=15) oligometastatic disease to supraclavicular (SCV) nodes, or with recurrent disease in mediastinum (n=10) or lung (n=7). Three patients were treated for both SCV and mediastinal sites, and six patients were treated for para-aortic or pelvic recurrences along with oligometastatic sites. Most received chemotherapy: induction (n=5), concurrent (n=24), or adjuvant (n=5). Outcomes were evaluated via Kaplan-Meier, and associations were examined via Cox proportional hazards modeling. RESULTS: Median follow-up was 35.2months (range 3.1-94.7). Median overall survival (OS) was 50.7months from end of RT, with 2-year and 3-year OS rates of 74% and 65%. Median progression-free survival (PFS) was 21.7months, with 1-year and 2-year PFS rates of 63% and 48%. Of the 38 patients, 21 (55%) experienced progression, at a median time of 24.8months. There was one in-field failure. Other relapses occurred regionally (n=10) and distally (n=12), with two patients experiencing both. The most common site of recurrence following treatment of SCV disease was mediastinum (n=7). The incidence of grade≥3 toxicity from treatment of oligometastatic sites was <3%. CONCLUSIONS: Definitive RT to sites of oligometastatic cervical cancer can result in excellent local control, favorable outcomes, and even achieve long-term survival for carefully selected patients, with minimal RT-associated toxicity.
引用
- Ning MS, Ahobila V, Jhingran A, et al. Outcomes and patterns of relapse after definitive radiation therapy for oligometastatic cervical cancer. Gynecol Oncol. 2017. PMID: 29089122. doi:10.1016/j.ygyno.2017.10.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。